We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

38 hedge funds and large institutions have $11.5M invested in VYNE Therapeutics in 2025 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 15 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

114% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 7

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

9% more funds holding

Funds holding: 35 → 38 (+3)

0.81% less ownership

Funds ownership: 47.9% → 47.09% (-0.81%)

51% less capital invested

Capital invested by funds: $23.4M → $11.5M (-$12M)

Holders
38
Holders Change
+3
Holders Change %
+8.57%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
15
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DCM
DAFNA Capital Management
California
+$1.57M
2
ACA
Acorn Capital Advisors
New York
+$810K
3
PSC
Patient Square Capital
California
+$633K
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$468K
5
EAM
Exome Asset Management
New York
+$269K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$4.67M
2
UOC
UBS O'Connor
Illinois
-$493K
3
Citadel Advisors
Citadel Advisors
Florida
-$320K
4
SSA
Schonfeld Strategic Advisors
New York
-$226K
5
Jane Street
Jane Street
New York
-$68K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Shay Capital
New York
$28.5K +$44.3K +18,015 New
Bank of America
27
Bank of America
North Carolina
$27.1K +$38.6K +15,672 +1,051%
State Street
28
State Street
Massachusetts
$24.9K – – –
Morgan Stanley
29
Morgan Stanley
New York
$20.2K +$20.9K +8,512 +198%
UBS Group
30
UBS Group
Switzerland
$12K +$17.1K +6,945 +1,101%
JP Morgan Chase
31
JP Morgan Chase
New York
$9.45K +$13.9K +5,667 +1,805%
TRCT
32
Tower Research Capital (TRC)
New York
$6.79K +$7.16K +2,910 +210%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$4K -$56.1K -22,789 -90%
MLA
34
MB, Levis & Associates
Pennsylvania
$1.65K – – –
Carson Wealth (CWM LLC)
35
Carson Wealth (CWM LLC)
Nebraska
$1K – – –
CA
36
Centerpoint Advisors
Massachusetts
$1K – – –
Wells Fargo
37
Wells Fargo
California
$103 – – –
TC
38
Truvestments Capital
Florida
$40 +$62 +25 New
CAM
39
Cormorant Asset Management
Massachusetts
– -$4.67M -1,394,336 Closed
Jane Street
40
Jane Street
New York
– -$68K -20,286 Closed
BL
41
BFSG LLC
California
– -$11.7K -3,500 Closed
Fidelity Investments
42
Fidelity Investments
Massachusetts
– -$17 -5 Closed
1
2

VYNE Hedge Fund Activity: Q1 2025 in Review

38 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2025, worth a combined $11.5M — down 51% from $23.4M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new VYNE positions and 4 closed out — a net gain of 3 holders — while 15 added to existing stakes and 7 trimmed.

The largest buyer was DAFNA Capital Management, opening a new position worth an estimated $1.57M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $4.67M sold.

  • 38 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2025, up from 35 in Q4 2024.
  • Funds reported $11.5M of VYNE Therapeutics stock for Q1 2025, down 51% quarter-over-quarter.
  • 7 funds opened new VYNE Therapeutics positions in Q1 2025 and 4 closed out, a net change of +3 holders.
  • The largest VYNE Therapeutics buyer in Q1 2025 was DAFNA Capital Management, an estimated $1.57M added.
  • The largest VYNE Therapeutics seller in Q1 2025 was Cormorant Asset Management, an estimated $4.67M sold.

Based on aggregated 13F filings for Q1 2025.